FCMI
SAGE

Foresite Capital Management II’s Sage Therapeutics SAGE Stock Holding History

Foresite Capital Management II’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-144,569
Closed -$5.29M – 18
2014
Q4 		$5.29M Buy
+144,569
New +$5.39M 3.62% 9

Other funds holding SAGE

TRV
Third Rock Ventures Boston, Massachusetts $1.07B AUM 170.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
ORI
Oak Ridge Investments Chicago, Illinois $1.51B AUM 37.25% 1-Year Est. Return
RIM
RS Investment Management San Francisco, California $9.73B AUM 3.24% 1-Year Est. Return

Foresite Capital Management II's SAGE Position: Q1 2015 in Review

Foresite Capital Management II sold out of Sage Therapeutics (SAGE) in Q1 2015, closing a stake of 144,569 shares — an estimated $5.29M sold.

Foresite Capital Management II first reported a position in SAGE in Q4 2014 and held it in 1 quarter. The position peaked at $5.29M in Q4 2014. 92 funds tracked by Wall St. Rank hold SAGE as of Q1 2015.

  • Foresite Capital Management II reported no remaining Sage Therapeutics position as of Q1 2015 after selling out during the quarter.
  • Foresite Capital Management II sold 144,569 Sage Therapeutics shares in Q1 2015, an estimated $5.29M.
  • Foresite Capital Management II first reported a position in Sage Therapeutics in Q4 2014 and held it in 1 quarter.
  • Foresite Capital Management II's Sage Therapeutics position peaked at $5.29M in Q4 2014.
  • 92 funds tracked by Wall St. Rank held Sage Therapeutics as of Q1 2015.

Based on Foresite Capital Management II's 13F filing for Q1 2015, filed 5 May 2015.